$1.27 Billion is the total value of Sarissa Capital Management LP's 10 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALKS | Buy | ALKERMES PLC | $407,489,000 | +40.0% | 13,213,000 | +11.3% | 31.99% | +38.2% |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $214,053,000 | +1.5% | 16,390,000 | 0.0% | 16.80% | +0.2% | |
| GILD | Buy | GILEAD SCIENCES INC | $207,266,000 | +11.6% | 2,967,300 | +10.0% | 16.27% | +10.2% |
| BIIB | BIOGEN INC | $181,963,000 | -18.3% | 643,000 | 0.0% | 14.28% | -19.3% | |
| INVA | Buy | INNOVIVA INC | $110,520,000 | +28.5% | 6,614,000 | +3.1% | 8.68% | +26.8% |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS INC | $56,427,000 | -16.2% | 3,926,700 | -7.8% | 4.43% | -17.3% |
| AMRN | New | AMARIN CORP PLCspons adr new | $43,350,000 | – | 8,500,000 | +100.0% | 3.40% | – |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $40,542,000 | -25.5% | 4,299,297 | +7.3% | 3.18% | -26.4% |
| VOR | VOR BIOPHARMA INC | $11,086,000 | -15.9% | 707,010 | 0.0% | 0.87% | -17.0% | |
| RGLS | REGULUS THERAPEUTICS INC | $1,279,000 | -15.1% | 1,851,851 | 0.0% | 0.10% | -16.7% | |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS INC | $0 | – | -950 | -100.0% | -0.00% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -1,000 | -100.0% | -0.01% | – |
| JAZZ | Exit | JAZZ PHARMACEUTICALS PLC | $0 | – | -1,000 | -100.0% | -0.01% | – |
| SRSAW | Exit | SARISSA CAPITAL ACQUISITN COw exp 10/23/202 | $0 | – | -3,333,333 | -100.0% | -0.40% | – |
| ALXN | Exit | Alexion Pharmaceuticals Inc | $0 | – | -650,440 | -100.0% | -9.50% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.